Glatiramer acetat (Serbian Wikipedia)

Analysis of information sources in references of the Wikipedia article "Glatiramer acetat" in Serbian language version.

refsWebsite

Global rank Serbian rank

4web.archive.org

1^st place

1^st place

4^th place

8^th place

low place

low place

447^th place

925^th place

1mcgraw-hill.com

low place

288^th place

1weizmann.ac.il

4,983^rd place

low place

1mult-sclerosis.org

low place

low place

low place

low place

399^th place

744^th place

7,609^th place

9,992^nd place

cochrane.org

„Cochrane Medical review of Copaxone”.

copaxone.com

„Prescribing Information” (PDF). Архивирано из оригинала (PDF) 7. 3. 2010. г. Приступљено 11. 6. 2010.
„FDA marketing label” (PDF). Архивирано из оригинала (PDF) 7. 3. 2010. г. Приступљено 11. 6. 2010.
„Copaxone marketing materials”. Архивирано из оригинала 17. 5. 2008. г. Приступљено 11. 6. 2010.

drugs.com

„Copaxone Side Effects”.

fda.gov

accessdata.fda.gov

„Full prescribing information copaxone (glatiramer acetate)” (PDF).

fda.gov

„FDA Copaxone Label” (PDF).

iguard.org

„iGuard.org TSQM survey results (n=1700+):”. ^{[мртва веза]}

mcgraw-hill.com

books.mcgraw-hill.com

Keith Parker; Laurence Brunton; Goodman, Louis Sanford; Lazo, John S.; Gilman, Alfred (2006). „Chapter 52. Immunosuppressants, tolerogens, and immunostimulants, A case study: Immunotherapy for multiple sclerosis”. Goodman & Gilman's The Pharmacological Basis of Therapeutics (11. изд.). New York: McGraw-Hill. ISBN 0071422803.

mult-sclerosis.org

„www.mult-sclerosis.org”.

nih.gov

ncbi.nlm.nih.gov

Comi G, Martinelli V, Rodegher M, Moiola L, Bajenaru O, Carra A, Elovaara I, Fazekas F, Hartung HP, Hillert J, King J, Komoly S, Lubetzki C, Montalban X, Myhr KM, Ravnborg M, Rieckmann P, Wynn D, Young C, Filippi M (2009). PreCISe study group.. „Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial”. Lancet. 374: 1503—11. PMID 19815268.
Johnson, KP (2010). „Risks vs benefits of glatiramer acetate: a changing perspective as new therapies emerge for multiple sclerosis”. Ther Clin Risk Manag. volume=15 (6): 153—72. PMID 20421914.
Lackner P, Part A, Burger C, Dietmann A, Broessner G, Helbok R, Reindl M, Schmutzhard E, Beer R (2009). „Glatiramer acetate reduces the risk for experimental cerebral malaria: a pilot study.”. Malar J. 8. PMID 19250545.

web.archive.org

„The chemistry of the Copaxone drug” (PDF). Архивирано из оригинала (PDF) 13. 8. 2006. г.
„Prescribing Information” (PDF). Архивирано из оригинала (PDF) 7. 3. 2010. г. Приступљено 11. 6. 2010.
„FDA marketing label” (PDF). Архивирано из оригинала (PDF) 7. 3. 2010. г. Приступљено 11. 6. 2010.
„Copaxone marketing materials”. Архивирано из оригинала 17. 5. 2008. г. Приступљено 11. 6. 2010.

weizmann.ac.il

„The chemistry of the Copaxone drug” (PDF). Архивирано из оригинала (PDF) 13. 8. 2006. г.